drugset / Trial / NCT06424444
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
Timeline
- Start
- 2024-04-29
- Primary completion
- 2024-11-03
- Completion
- 2024-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Reproxalap | Other / unclassified | 0.25 % | Other |